drugset / Trial / NCT01856933
BrUOG 263: Prostate Specific Membrane Antigen (PSMA) Glioblastoma Multiforme (GBM)
Phase 2
Completed
6 enrolled
Heinrich Elinzano, MD
Progenics Pharmaceuticals, Inc. · collabRhode Island Hospital · collabUniversity of Texas · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the effectiveness of Prostate Specific Membrane Antigen (PSMA ADC), as well as its safety and side effects for patients with advanced brain tumors. This study will also study how your body metabolizes (breaks down) PSMA ADC.
Timeline
- Start
- 2013-05
- Primary completion
- 2014-11
- Completion
- 2015-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PSMA ADC | Other / unclassified | 2.5 mg/kg | Intravenous |